Olmesartan-associated sprue-like enteropathy: An emerging cause of drug-induced chronic diarrhea

Solano-Iturri, Goizalde; García-Jiménez, Nicanor; Solano-Iturri, Jon Danel; Blanco-Sampascual, Sonia

doi:10.1016/j.rgmxen.2017.03.009

Cited by 4 publications

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This interruption in turn acts as a distractor, allowing the patient to notice clinical improvement for reasons that may not be obvious to the treatment team only to have the drug subsequently resumed and further postpone the diagnosis. Another circumstance which may delay diagnosis is when patients undergo endoscopy without biopsy, as has been previously described [16]. This may occur if endoscopic findings appear normal.…”

Section: Basharimentioning

confidence: 99%

Severe Sprue-Like Enteropathy and Colitis due to Olmesartan: Lessons Learned From a Rare Entity

Bashari

2020

Gastroenterol Res

View full text Add to dashboard Cite

Olmesartan is an angiotensin II receptor blocker (ARB) drug approved in 2002 for the treatment of hypertension. Since 2012, there have been reports of a rare adverse effect suspected to be related to its use. The author presents a case of a 63-year-old female with refractory gastrointestinal (GI) symptoms including diarrhea with associated weight loss and severe electrolyte abnormalities necessitating hospitalization. An extensive inpatient evaluation ensued and was initially unremarkable. Esophagogastroduodenoscopy (EGD) discovered an endoscopically normal duodenum that was biopsied and notably revealed villous atrophy and intraepithelial lymphocytosis. Colonoscopy was normal appearing though biopsy findings were significant for nonspecific colitis. The endoscopy findings in the setting of the clinical presentation confirmed the diagnosis of olmesartan-associated enteropathy (OAE). Clinical improvement was noted after cessation of olmesartan and histological resolution was confirmed with repeat EGD post-discharge.

show abstract

Section: Basharimentioning

confidence: 99%

Severe Sprue-Like Enteropathy and Colitis due to Olmesartan: Lessons Learned From a Rare Entity

Bashari

2020

Gastroenterol Res

View full text Add to dashboard Cite

show abstract

“…The late onset of symptoms from the start of treatment suggests that it is an immune-mediated sensitivity 13. Solano-Iturri et al14 postulated that it could be the result of an immune injury, with an increased CD8 +T cell count and IL-15 overexpression in epithelial cells. Both, clinical and histological alterations resolved after drug discontinuation 15.…”

Section: Discussionmentioning

confidence: 99%

Telmisartan-induced sprue-like enteropathy: a case report

et al. 2018

View full text Add to dashboard Cite

A possible case of sprue-like enteropathy (SLE) induced by the use of telmisartan is reported. Telmisartan is an angiotensin-receptor II blocker (type 1) used for the treatment of hypertension. Several cases of SLE associated with olmesartan and other drugs of the same group have been reported. In all cases, SLE resolved following therapy withdrawal. We describe the case of an 80-year-old woman who presented with diarrhoea and abdominal pain. In the past 5 years she had been treated with telmisartan 40 mg once a day for hypertension, so we hypothesised that symptoms might be caused by telmisartan. After treatment discontinuation, diarrhoea disappeared. Three causality algorithms were applied and revealed a possible or likely causal relationship. At present, the patient remains asymptomatic. There is a causal relationship between the use of telmisartan and SLE. This association should be taken into account by physicians when prescribing and reviewing drug therapies.

show abstract